Notice: This company recently went public with an IPO on Friday, January 31st 2025. They issued 8,750,000 shares at $16.00 per share. We will continue to update data for MAZE as it becomes available. Maze Therapeutics (MAZE) Competitors $12.96 -0.42 (-3.14%) As of 02/10/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends MAZE vs. BHC, HCM, IBRX, CGON, BEAM, PTGX, HRMY, JANX, TARS, and IDYAShould you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include Bausch Health Companies (BHC), HUTCHMED (HCM), ImmunityBio (IBRX), CG Oncology (CGON), Beam Therapeutics (BEAM), Protagonist Therapeutics (PTGX), Harmony Biosciences (HRMY), Janux Therapeutics (JANX), Tarsus Pharmaceuticals (TARS), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Maze Therapeutics vs. Bausch Health Companies HUTCHMED ImmunityBio CG Oncology Beam Therapeutics Protagonist Therapeutics Harmony Biosciences Janux Therapeutics Tarsus Pharmaceuticals IDEAYA Biosciences Bausch Health Companies (NYSE:BHC) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership, community ranking and profitability. Does the MarketBeat Community favor BHC or MAZE? Bausch Health Companies received 359 more outperform votes than Maze Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformBausch Health CompaniesOutperform Votes35961.26% Underperform Votes22738.74% Maze TherapeuticsN/AN/A Do analysts recommend BHC or MAZE? Bausch Health Companies currently has a consensus target price of $7.42, indicating a potential upside of 17.45%. Given Bausch Health Companies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Bausch Health Companies is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Companies 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of BHC or MAZE? 78.7% of Bausch Health Companies shares are held by institutional investors. 8.1% of Bausch Health Companies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor BHC or MAZE? In the previous week, Bausch Health Companies had 3 more articles in the media than Maze Therapeutics. MarketBeat recorded 5 mentions for Bausch Health Companies and 2 mentions for Maze Therapeutics. Bausch Health Companies' average media sentiment score of 0.27 beat Maze Therapeutics' score of -0.50 indicating that Bausch Health Companies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Companies 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maze Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Which has higher valuation and earnings, BHC or MAZE? Maze Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch Health Companies$8.76B0.26-$592M-$0.48-13.16Maze TherapeuticsN/AN/AN/AN/AN/A Is BHC or MAZE more profitable? Maze Therapeutics has a net margin of 0.00% compared to Bausch Health Companies' net margin of -1.88%. Maze Therapeutics' return on equity of 0.00% beat Bausch Health Companies' return on equity.Company Net Margins Return on Equity Return on Assets Bausch Health Companies-1.88% -755.86% 5.11% Maze Therapeutics N/A N/A N/A SummaryBausch Health Companies beats Maze Therapeutics on 9 of the 11 factors compared between the two stocks. Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAZE vs. The Competition Export to ExcelMetricMaze Therapeutics IndustryMedical SectorNASDAQ ExchangeMarket Cap$567.39M$2.25B$5.69B$9.04BDividend YieldN/A13.98%5.30%4.01%P/E RatioN/A10.5689.7819.46Price / SalesN/A144.261,038.3174.18Price / CashN/A15.2346.0638.79Price / BookN/A2.405.134.78Net IncomeN/A$76.47M$113.50M$222.19M7 Day PerformanceN/A4.78%0.42%1.42%1 Month PerformanceN/A6.22%3.65%2.91%1 Year PerformanceN/A10.47%22.50%20.50% Maze Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAZEMaze TherapeuticsN/A$12.96-3.1%N/AN/A$567.39MN/A0.00121BHCBausch Health Companies4.1122 of 5 stars$6.45-1.5%$7.42+15.1%-23.1%$2.33B$9.47B-13.4320,270Gap DownHCMHUTCHMED3.2834 of 5 stars$13.24-5.2%$19.00+43.5%-4.2%$2.31B$838M0.001,988Positive NewsIBRXImmunityBio2.3042 of 5 stars$3.36+1.5%$13.58+304.3%-26.0%$2.31B$620,000.000.00590CGONCG Oncology2.4339 of 5 stars$28.89-3.8%$63.88+121.1%-32.0%$2.28B$684,000.000.0061Positive NewsBEAMBeam Therapeutics2.899 of 5 stars$27.41-0.9%$47.67+73.9%-8.5%$2.27B$349.64M-15.57510PTGXProtagonist Therapeutics3.8424 of 5 stars$38.88+3.0%$56.00+44.0%+42.3%$2.25B$60M14.62120HRMYHarmony Biosciences4.6112 of 5 stars$37.45-3.4%$55.00+46.9%+14.0%$2.21B$681.88M17.75200Positive NewsJANXJanux Therapeutics3.6103 of 5 stars$39.37-3.2%$89.90+128.3%+300.8%$2.07B$8.08M-33.6530Gap UpTARSTarsus Pharmaceuticals1.2454 of 5 stars$52.95-0.7%$56.00+5.8%+66.2%$2.04B$17.45M0.0050Analyst ForecastPositive NewsIDYAIDEAYA Biosciences3.8543 of 5 stars$23.00-4.0%$53.67+133.3%-51.1%$1.99B$3.92M-9.8780Upcoming EarningsAnalyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies Bausch Health Companies Competitors HUTCHMED Competitors ImmunityBio Competitors CG Oncology Competitors Beam Therapeutics Competitors Protagonist Therapeutics Competitors Harmony Biosciences Competitors Janux Therapeutics Competitors Tarsus Pharmaceuticals Competitors IDEAYA Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MAZE) was last updated on 2/11/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredTrump’s “Shock and Awe” Executive OrderPresident Trump has already launched a "shock and awe" flurry of new Executive Orders... He's withdrawn fro...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
